Scancell Holdings has received CTA from the UK MHRA for a Phase III trial evaluating its ImmunoBody, iSCIB1+, in advanced melanoma patients.

The post UK MHRA grants approval for Scancell’s Phase III study of iSCIB1+ appeared first on Clinical Trials Arena.